# Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

> **NCT00398489** · PHASE2 · UNKNOWN · sponsor: **Technical University of Munich** · enrollment: 94 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** anastrozole
- **DRUG:** cyclophosphamide
- **DRUG:** docetaxel
- **DRUG:** epirubicin hydrochloride
- **DRUG:** goserelin acetate
- **DRUG:** tamoxifen citrate
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00398489
- **Lead sponsor:** Technical University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2010-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398489, "Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00398489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*